Guardant Health (GH) investors have a new number to think about this week. Bernstein SocGen Group raised its price target on the cancer-screening company's stock to $200 a share, up from $175.
For Q2, according to Seeking Alpha, analysts are expecting normalized EPS of $1.28, GAAP EPS of $0.97, and $12.52bn of ...
Woman's World on MSN
Colon cancer screening guidelines changed: What women over 40 need to know
Colon cancer used to feel like a worry for later-something to think about decades down the road. Not anymore. An estimated ...
They told me it was effective, and I knew mailing a Cologuard box back would be pretty dang easy.” Cologuard — a simple way ...
The nationwide rollout, which Labcorp disclosed Monday, comes weeks after the Centers for Medicare and Medicaid Services approved coverage for ColoSense, and the American Cancer Society named the test ...
The American Cancer Society released updated guidelines for colorectal cancer screening, adding options for a blood-based ...
Unfortunately, Grail had bad news for investors in February when it released top-line results from the NHS and outlined that it had missed its primary endpoint of demonstrating "statistically ...
Following the close, the company gained a broad portfolio and differentiated pipeline aimed at early detection of cancer and personalized treatment decisions. This includes Cologuard, a non-invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results